Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR [2]

Leukemia

Volumn 19, Issue 11, 2005, Pages 1988-1990

  Boeckx, Nancy ^a   De Roover, J ^a   van der Velden, V H J ^b   Maertens, J ^a   Uyttebroeck, A ^a   Vandenberghe, P ^a,c   van Dongen, J J M ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYTARABINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; HYBRID PROTEIN; MITOXANTRONE; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; LETTER; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCHOOL CHILD; SCORING SYSTEM;

EID: 27644493329     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403961     Document Type: Letter

References (10)

1. Poirel H, Radford-Weiss I, Rack K, Troussard X, Veil A, Valensi F et al. Detection of the chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995; 85: 1313-1322.
2. Mrozek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol 2000; 72: 261-271.
3. Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443-449.
4. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746-2755.
5. Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000; 95: 815-819.
6. Leroy H, Botton SD, Grardel-Duflos N, Darre S, Leleu X, Roumier C et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005; 19: 367-372.
7. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S et al. Quantitative real-time RT-PCR analysis of PML-RARalpha mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521-2528.
8. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for minimal residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 2003; 12: 2318-2357.
9. Lo-Coco F, Breccia M, Diverio D. The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 503-520.
10. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.